# Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

> **NCT00469014** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 72 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Clofarabine
- **DRUG:** Busulfan
- **DRUG:** Fludarabine
- **OTHER:** Stem Cell Infusion
- **DRUG:** Thymoglobulin (ATG)
- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT00469014
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2021-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00469014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00469014, "Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00469014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*